KCNA10

Summary

KCNA10 (potassium voltage-gated channel subfamily A member 10, HGNC:6219) is a protein-coding gene on chromosome 1p13.3, encoding Potassium voltage-gated channel subfamily A member 10 (Q16322). Voltage-gated potassium ion channel that mediates K(+) permeability of excitable membranes. It is a selective cancer dependency (DepMap: 15.2% of cell lines).

Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It is specifically regulated by cGMP and postulated to mediate the effects of substances that increase intracellular cGMP. This gene is intronless, and the gene is clustered with genes KCNA2 and KCNA3 on chromosome 1.

Source: NCBI Gene 3744 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 93 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 15.2% of screened cell lines
• MANE Select transcript: NM_005549

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6219
Approved symbol	KCNA10
Name	potassium voltage-gated channel subfamily A member 10
Location	1p13.3
Locus type	gene with protein product
Status	Approved
Aliases	Kv1.8
Ensembl gene	ENSG00000143105
Ensembl biotype	protein_coding
OMIM	602420
Entrez	3744

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000369771

RefSeq mRNA: 1 — MANE Select: NM_005549 NM_005549

CCDS: CCDS826

Canonical transcript exons

ENST00000369771 — 1 exons

Exon	Start	End
ENSE00001450849	110517217	110519175

Expression profiles

Bgee: expression breadth tissue_specific, 4 present calls, max score 72.76.

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	72.76	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	71.33	gold quality
tendon of biceps brachii	UBERON:0008188	70.67	gold quality
myocardium	UBERON:0002349	66.82	gold quality
vena cava	UBERON:0004087	66.07	gold quality
sperm	CL:0000019	65.47	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	64.49	gold quality
secondary oocyte	CL:0000655	64.24	gold quality
biceps brachii	UBERON:0001507	63.79	gold quality
oocyte	CL:0000023	63.63	gold quality
nipple	UBERON:0002030	61.91	gold quality
substantia nigra pars reticulata	UBERON:0001966	61.66	gold quality
ventral tegmental area	UBERON:0002691	61.25	gold quality
deltoid	UBERON:0001476	61.14	gold quality
saphenous vein	UBERON:0007318	61.09	gold quality
lateral globus pallidus	UBERON:0002476	60.95	gold quality
substantia nigra pars compacta	UBERON:0001965	60.92	gold quality
pharyngeal mucosa	UBERON:0000355	60.86	gold quality
subthalamic nucleus	UBERON:0001906	60.59	gold quality
pericardium	UBERON:0002407	60.40	gold quality
nasal cavity epithelium	UBERON:0005384	60.24	gold quality
inferior vagus X ganglion	UBERON:0005363	60.14	gold quality
parotid gland	UBERON:0001831	60.11	gold quality
cartilage tissue	UBERON:0002418	59.99	gold quality
dorsal plus ventral thalamus	UBERON:0001897	59.97	gold quality
cerebellar vermis	UBERON:0004720	59.95	gold quality
thymus	UBERON:0002370	59.93	gold quality
pylorus	UBERON:0001166	59.92	gold quality
pons	UBERON:0000988	59.90	gold quality
trigeminal ganglion	UBERON:0001675	59.88	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.82

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 15.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• KCNA10 in human proximal tubular cells, glomerular and vascular endothelial cells, and also in vascular smooth muscle cells. (PMID:12444201)
• Association of Single Nucleotide Polymorphisms in KCNA10 and SLC13A3 Genes with the Susceptibility to Chronic Kidney Disease of Unknown Etiology in Central Indian Patients. (PMID:36696070)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Kcna10	ENSMUSG00000042861
rattus_norvegicus	Kcna10	ENSRNOG00000050416

Paralogs (31): KCNG1 (ENSG00000026559), KCNQ1 (ENSG00000053918), KCNQ2 (ENSG00000075043), KCND1 (ENSG00000102057), KCNA7 (ENSG00000104848), KCNA1 (ENSG00000111262), KCNC4 (ENSG00000116396), KCNQ4 (ENSG00000117013), KCNS1 (ENSG00000124134), KCNC1 (ENSG00000129159), KCNA5 (ENSG00000130037), KCNC3 (ENSG00000131398), KCNA6 (ENSG00000151079), KCNS2 (ENSG00000156486), KCNB1 (ENSG00000158445), KCNF1 (ENSG00000162975), KCNV1 (ENSG00000164794), KCNC2 (ENSG00000166006), KCNV2 (ENSG00000168263), KCNG4 (ENSG00000168418), KCNS3 (ENSG00000170745), KCNG3 (ENSG00000171126), KCND3 (ENSG00000171385), KCNA3 (ENSG00000177272), KCNA2 (ENSG00000177301), KCNG2 (ENSG00000178342), KCNA4 (ENSG00000182255), KCNB2 (ENSG00000182674), KCNQ3 (ENSG00000184156), KCND2 (ENSG00000184408), KCNQ5 (ENSG00000185760)

Protein

Protein identifiers

Potassium voltage-gated channel subfamily A member 10 — Q16322 (reviewed: Q16322)

Alternative names: Voltage-gated potassium channel subunit Kv1.8

All UniProt accessions (1): Q16322

UniProt curated annotations — full annotation on UniProt →

Function. Voltage-gated potassium ion channel that mediates K(+) permeability of excitable membranes. When opened in response to the voltage difference across the membrane, KCNA10 channel selectively allows the flow of potassium ions across the membrane down their electrochemical gradient.

Subunit / interactions. Homotetramer. Interacts with KCN4B/POMP. Interaction with KCN4B/POMP is necessary for the modulation of channel activity by cAMP.

Subcellular location. Membrane.

Tissue specificity. Detected in kidney, in proximal tubules, glomerular endothelium, in vascular endothelium and in smooth muscle cells.

Activity regulation. The channel activity is up-regulated by cAMP.

Domain organisation. The N-terminus may be important in determining the rate of inactivation of the channel while the tail may play a role in modulation of channel activity and/or targeting of the channel to specific subcellular compartments. The segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.

Similarity. Belongs to the potassium channel family. A (Shaker) (TC 1.A.1.2) subfamily. Kv1.8/KCNA10 sub-subfamily.

RefSeq proteins (1): NP_005540* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR003131	T1-type_BTB	Domain
IPR003968	K_chnl_volt-dep_Kv	Family
IPR003972	K_chnl_volt-dep_Kv1	Family
IPR005821	Ion_trans_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR027359	Volt_channel_dom_sf	Homologous_superfamily
IPR028325	VG_K_chnl	Family

Pfam: PF00520, PF02214

Catalyzed reactions (Rhea), 1 shown:

• K(+)(in) = K(+)(out) (RHEA:29463)

UniProt features (17 total): transmembrane region 6, glycosylation site 3, sequence variant 3, region of interest 2, chain 1, lipid moiety-binding region 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16322-F1	77.53	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 293

Glycosylation sites (3): 256, 334, 498

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1296072	Voltage gated Potassium channels
R-HSA-112316	Neuronal System
R-HSA-1296071	Potassium Channels

MSigDB gene sets: 54 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS, REACTOME_POTASSIUM_CHANNELS, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_PROTEIN_HOMOOLIGOMERIZATION, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_POTASSIUM_CHANNEL_COMPLEX, GOBP_REGULATION_OF_MEMBRANE_POTENTIAL, GOCC_CATION_CHANNEL_COMPLEX, GOCC_TRANSPORTER_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_PLASMA_MEMBRANE_PROTEIN_COMPLEX, GOMF_VOLTAGE_GATED_MONOATOMIC_CATION_CHANNEL_ACTIVITY, GOMF_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_GATED_CHANNEL_ACTIVITY

GO Biological Process (7): action potential (GO:0001508), potassium ion transport (GO:0006813), protein homooligomerization (GO:0051260), potassium ion transmembrane transport (GO:0071805), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085)

GO Molecular Function (6): intracellularly cyclic nucleotide-activated monoatomic cation channel activity (GO:0005221), voltage-gated potassium channel activity (GO:0005249), delayed rectifier potassium channel activity (GO:0005251), monoatomic ion channel activity (GO:0005216), potassium channel activity (GO:0005267), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), voltage-gated potassium channel complex (GO:0008076), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Potassium Channels	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	2
regulation of membrane potential	1
metal ion transport	1
protein complex oligomerization	1
potassium ion transport	1
monoatomic cation transmembrane transport	1
monoatomic ion transport	1
transmembrane transport	1
cellular process	1
intracellularly ligand-gated monoatomic ion channel activity	1
cyclic nucleotide-activated monoatomic ion channel activity	1
ligand-gated monoatomic cation channel activity	1
potassium channel activity	1
voltage-gated monoatomic cation channel activity	1
voltage-gated potassium channel activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
monoatomic cation channel activity	1
potassium ion transmembrane transporter activity	1
binding	1
membrane	1
cell periphery	1
potassium channel complex	1
plasma membrane protein complex	1
cellular anatomical structure	1
transmembrane transporter complex	1

Protein interactions and networks

STRING

1360 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KCNA10	ZNF705D	P0CH99	446
KCNA10	KCNA2	P16389	397
KCNA10	KCNH5	Q8NCM2	396
KCNA10	KCNH8	Q96L42	393
KCNA10	IQCC	Q4KMZ1	372
KCNA10	TPBGL	P0DKB5	367
KCNA10	KCNAB2	Q13303	360
KCNA10	OCM2	P0CE71	359
KCNA10	KCNAB1	Q14722	357
KCNA10	PROSER3	Q2NL68	351
KCNA10	KCNH3	Q9ULD8	343
KCNA10	KCNH4	Q9UQ05	342
KCNA10	SLC26A5	P58743	328
KCNA10	SLC13A3	Q8WWT9	325
KCNA10	CCDC9B	Q6ZUT6	308

IntAct

20 interactions, top by confidence:

A	B	Type	Score
KCNA10	DOLK	psi-mi:“MI:0915”(physical association)	0.560
TMBIM6	KCNA10	psi-mi:“MI:0915”(physical association)	0.560
KCNA1	KCNA10	psi-mi:“MI:0915”(physical association)	0.560
MAL	KCNA10	psi-mi:“MI:0915”(physical association)	0.560
SGTA	KCNA10	psi-mi:“MI:0915”(physical association)	0.560
KCNA10	GAPDHS	psi-mi:“MI:0914”(association)	0.530
DOLK	KCNA10	psi-mi:“MI:0915”(physical association)	0.000
TMBIM6	KCNA10	psi-mi:“MI:0915”(physical association)	0.000
KCNA1	KCNA10	psi-mi:“MI:0915”(physical association)	0.000
MAL	KCNA10	psi-mi:“MI:0915”(physical association)	0.000
SGTA	KCNA10	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (37): REEP1 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), FAM63A (Affinity Capture-MS), SLMAP (Affinity Capture-MS), NAT14 (Affinity Capture-MS), CHSY1 (Affinity Capture-MS), GOLM1 (Affinity Capture-MS), C1orf43 (Affinity Capture-MS), SLC12A9 (Affinity Capture-MS), REEP4 (Affinity Capture-MS), KCNAB2 (Affinity Capture-MS), GAPDHS (Affinity Capture-MS), LEMD2 (Affinity Capture-MS), CASP3 (Affinity Capture-MS), B3GALT6 (Affinity Capture-MS)

ESM2 similar proteins: B2RQA1, D4ADX7, G5EFC3, O35119, O35174, O88759, P08510, P10499, P15384, P15385, P16388, P16389, P16390, P17658, P17659, P19024, P22001, P22459, P22462, P22739, P25122, P34586, P48994, P63141, P63142, P79100, Q05037, Q09081, Q09470, Q14B80, Q16322, Q25452, Q28293, Q28527, Q61423, Q61762, Q61923, Q7T199, Q7TSH7, Q8BQZ8

Diamond homologs: A4K2M4, A4K2P6, A4K2T1, A4K2Y2, A6H8H5, B2RQA1, G5EFC3, O18868, O35174, O43526, O88759, O88943, O97531, P08510, P10499, P15384, P15385, P15387, P15388, P16388, P16389, P16390, P17658, P17659, P17970, P17971, P17972, P19024, P22001, P22459, P22460, P22462, P22739, P25122, P48547, P50638, P56696, P59994, P59995, P63141

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	2
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

117 predictions. Top by Δscore:

Variant	Effect	Δscore
1:110517884:T:A	donor_gain	0.6300
1:110517919:A:T	donor_gain	0.5400
1:110517969:C:CT	acceptor_gain	0.5200
1:110517922:C:CT	donor_gain	0.5100
1:110517964:TC:T	donor_gain	0.5000
1:110517965:CC:C	donor_gain	0.5000
1:110518040:C:CT	donor_gain	0.4700
1:110517923:G:T	donor_gain	0.4500
1:110517945:C:CT	donor_gain	0.4500
1:110518041:C:CT	donor_gain	0.4500
1:110517752:CCAGG:C	donor_gain	0.4200
1:110517921:CCGGA:C	donor_gain	0.4100
1:110517543:TGCC:T	donor_gain	0.4000
1:110517601:G:C	donor_gain	0.4000
1:110517764:T:TA	donor_gain	0.3900
1:110517523:A:AC	donor_gain	0.3700
1:110517524:C:CC	donor_gain	0.3700
1:110517634:C:G	acceptor_gain	0.3700
1:110517692:G:A	donor_gain	0.3700
1:110517922:CGGAG:C	donor_gain	0.3600
1:110518037:TGAC:T	donor_gain	0.3600
1:110517636:A:T	acceptor_gain	0.3500
1:110517486:C:A	donor_gain	0.3400
1:110517751:A:AC	donor_gain	0.3400
1:110517752:C:CC	donor_gain	0.3400
1:110517822:CT:C	acceptor_gain	0.3400
1:110517824:C:CC	acceptor_gain	0.3400
1:110517836:T:C	acceptor_gain	0.3400
1:110517966:C:CT	acceptor_gain	0.3400
1:110517706:AGCC:A	donor_gain	0.3300

AlphaMissense

3406 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:110517408:G:C	F460L	1.000
1:110517408:G:T	F460L	1.000
1:110517409:A:C	F460C	1.000
1:110517409:A:G	F460S	1.000
1:110517410:A:G	F460L	1.000
1:110517433:G:C	P452R	1.000
1:110517433:G:T	P452H	1.000
1:110517436:A:G	L451P	1.000
1:110517436:A:T	L451H	1.000
1:110517439:G:T	A450D	1.000
1:110517448:A:G	L447P	1.000
1:110517448:A:T	L447H	1.000
1:110517454:C:A	G445V	1.000
1:110517454:C:T	G445E	1.000
1:110517455:C:A	G445W	1.000
1:110517455:C:G	G445R	1.000
1:110517455:C:T	G445R	1.000
1:110517463:G:T	A442D	1.000
1:110517465:A:C	C441W	1.000
1:110517466:C:T	C441Y	1.000
1:110517467:A:G	C441R	1.000
1:110517475:C:T	G438D	1.000
1:110517476:C:G	G438R	1.000
1:110517488:C:A	G434W	1.000
1:110517502:G:T	P429Q	1.000
1:110517514:C:A	G425V	1.000
1:110517514:C:T	G425E	1.000
1:110517520:C:T	G423D	1.000
1:110517521:C:G	G423R	1.000
1:110517535:G:A	T418I	1.000

dbSNP variants (sampled 300 via entrez): RS1001793431 (1:110520962 T>G), RS1002396549 (1:110519465 C>G), RS1002743758 (1:110518494 C>G), RS1002774806 (1:110518670 G>A), RS1003193236 (1:110516767 C>G,T), RS1003747394 (1:110519781 A>C,G), RS1004826949 (1:110520916 G>C), RS1005706348 (1:110519984 G>A), RS1006190506 (1:110520801 A>G), RS1006634910 (1:110521117 A>C), RS1007410943 (1:110516948 C>T), RS1007658476 (1:110518344 A>G), RS1008344597 (1:110518040 C>A,G,T), RS1009704492 (1:110520048 G>A,T), RS1011272947 (1:110520974 C>G)

Disease associations

OMIM: gene MIM:602420 | disease phenotypes: MIM:192500

GenCC curated gene-disease

Mondo (1): familial long QT syndrome (MONDO:0019171)

Orphanet (2): Romano-Ward syndrome (Orphanet:101016), Congenital long QT syndrome (Orphanet:768)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003800_3	Response to bupropion in depression	5.000000e-07
GCST008019_4	Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome	5.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2362996 (PROTEIN FAMILY), CHEMBL2363001 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: vgic — Voltage-gated potassium channels (K_v)

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
charybdotoxin	Channel blocker	7.0	pIC50
pimozide	Channel blocker	6.5	pIC50
ketoconazole	Channel blocker	6.3	pIC50
verapamil	Channel blocker	4.3	pIC50
fampridine	Channel blocker	2.8	pIC50
Ba2+	Channel blocker	2.3	pIC50
tetraethylammonium	Channel blocker	1.3	pIC50

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.82	Ki	0.15	nM	CHEMBL5722941
9.74	IC50	0.18	nM	CHEMBL5722941

PubChem BioAssay actives

2 with measured affinity, of 35 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[(1R,2aS,4S,5aS,8aS,10S,11aR,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,87R,93S,96S,99S)-17a,20a,23a,53a,63-pentakis(4-aminobutyl)-31-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-16,29a,72,78-tetrakis(2-amino-2-oxoethyl)-14a,26a-bis(3-amino-3-oxopropyl)-2a,38a,66-tribenzyl-28,50a,57-tris[(2S)-butan-2-yl]-4,5a,19,42,45,69-hexakis(3-carbamimidamidopropyl)-51,54-bis(2-carboxyethyl)-56a,99-bis(carboxymethyl)-36-[[(2S,3S)-1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]carbamoyl]-39,60-bis[(1R)-1-hydroxyethyl]-75,93-bis(hydroxymethyl)-32a,35a,59a-tris[(4-hydroxyphenyl)methyl]-22-(1H-imidazol-4-ylmethyl)-96-(1H-indol-3-ylmethyl)-41a-methyl-25-(2-methylpropyl)-1a,3,4a,6,7a,9,10a,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,5,6a,8,9a,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.010,14.0144,148]nonahexacontahectan-8a-yl]propanoic acid	2198828: Binding affinity to KV channel (unknown origin) assessed as inhibition constant	ki	0.0001	uM

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation	1
4-O-methyl-12-O-tetradecanoylphorbol 13-acetate	increases transport, decreases reaction	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Barium	decreases reaction, increases transport	1
Benzo(a)pyrene	increases methylation	1
Pimozide	decreases reaction, increases transport	1
Plant Extracts	affects cotreatment, decreases expression	1
Potassium	decreases reaction, increases transport	1
Verapamil	decreases reaction, increases transport	1
4-Aminopyridine	decreases reaction, increases transport	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

22 unique, capped per target: 20 binding, 1 toxicity, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1787442	Binding	Inhibition of human recombinant Kv channel at 10 uM by radioligand binding assay	Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement. — Bioorg Med Chem Lett
CHEMBL5522525	Toxicity	Inhibition of human K+ channel by automated electrophysiology	Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure. — J Med Chem
CHEMBL4407437	ADMET	Inhibition of Kv1.8 (unknown origin) at 3 uM relative to control	Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1K0	PrecisION hKv1.8-CHO	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea